VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
AORTArtivion, Inc.
$23.61$1.1B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksAORTCash Flow

Artivion, Inc. (AORT) Cash Flow Statement

30Y historyFree accessUpdated daily

Cash flow generation remains inconsistent, highlighted by a significant $19.1 million working capital outflow in 2026Q1 and a historical peak capital intensity of 23.7% in 2025Q4.

AORT Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations56.24M38.13M22.24M18.82M-5.15M-2.58M12.37M15.83M9.88M10.8M19.72M11.44M8.12M16.77M18.99M16.75M20.84M16.57M9.54M9.29M-1.07M-18.52M-16.23M-5.93M-2.11M6.48M10.28M987K1.2M-2.2M4M
Operating CF Margin %-8.64%5.72%5.32%-1.64%-0.86%4.88%5.73%3.76%5.69%10.93%7.84%5.61%11.92%14.42%14%17.86%14.84%9.08%9.81%-1.32%-26.73%-26.01%-9.96%-2.71%7.39%13.33%1.48%1.98%-4.32%10.81%
Operating CF Growth %423.47%71.48%18.12%465.32%-99.34%-120.9%-21.85%60.18%-8.53%-45.22%72.34%40.95%-51.6%-11.68%13.37%-19.61%25.74%73.77%2.64%967.6%94.22%-14.12%-173.53%-181%-132.58%-36.97%941.44%-17.75%154.55%-155%263.64%
Net Income11.69M9.77M-13.36M-30.69M-19.19M-14.83M-3.46M1.72M-2.84M3.7M10.78M4M7.32M16.17M7.95M7.37M3.94M8.68M32.91M7.2M365K-19.54M-18.75M-32.29M-27.76M9.17M7.82M4.45M6.5M4.7M3.9M
Depreciation & Amortization23.35M22.46M24.2M23.08M22.44M23.98M27.86M18.32M18.09M9.74M8.38M5.86M6.03M5.84M5.63M4.96M3.94M4.26M4.35M4.46M4.84M5.04M5.48M5.51M5.42M4.61M3.22M3.15M3.5M2.7M1.4M
Stock-Based Compensation024.39M14.24M14.42M12.34M10.71M6.91M8.8M6.33M6.92M6.33M5.09M3.44M3.24M3.16M2.79M2.62M2.43M2.1M2.13M1.62M358K358K00000000
Deferred Taxes-487K37K-1.51M-1.39M-1.72M-4.47M4.28M-2.31M-4.49M-1.48M595K3.68M178K617K1.23M1.77M-1.51M5.25M-7K-961K226K3.55M7.19M5.73M-5.57M624K1.66M-970K-1.9M400K0
Other Non-Cash Items36.22M3.64M15.9M29.59M6.91M15.26M3.47M8.68M2.8M2.79M-6.28M718K-324K-7.52M1.31M1.04M7.73M652K-18.29M1.72M2.16M-2.48M10K347K38.01M348K616K1.19M-100K100K200K
Working Capital Changes-14.53M-22.16M-17.24M-16.19M-25.94M-33.23M-26.7M-19.38M-10.01M-10.87M-83K-7.91M-8.52M-1.58M-289K-1.17M4.11M-4.71M-11.52M-5.25M-10.28M-5.45M-10.52M7.9M-12.21M-8.98M-3.03M-6.84M-6.6M-10.1M-1.5M
Change in Receivables-2.11M-7.27M-15.39M-4.05M-13.34M-11.56M9.94M-3.38M-5.91M-7.26M4.14M-3.81M-4.56M-1.64M1.36M-2.23M179K-80.36M-68.24M2.78M-36.31M-29.87M-30.03M00000000
Change in Inventory-19.2M-15.28M-6.14M-14.36M-8.4M-18.38M-24.76M-8.13M2.38M-9.37M-9.46M-2.26M-1.13M193K-1.6M2.44M-1.8M-1.14M-2.92M-454K-600K158K-517K135K-1.43M-2.27M-1.43M-2.88M-3M-900K200K
Change in Payables9.53M2.18M9.5M1.68M-1.96M-1.89M-9.16M251K-8.87M8.73M4.72M-656K-64K572K529K-772K2.38M483K267K842K155K342K342K00000000
Cash from Investing-48.91M-42.04M-28.19M-502K-10.71M5.66M-73.13M-23.94M-6.71M-170.99M-73.85M-4.49M-5.35M10.88M-22.92M-27.72M-10.73M-4.38M-4.34M446K-557K-2.03M457K9.35M6.28M-18.1M-6.63M-3.28M-18.9M-9.6M-4.9M
Capital Expenditures-43.41M-39.04M-11.19M-7.43M-10.71M-13.09M-7.33M-8.07M-5.79M-7.04M-7.42M-4.1M-5.32M-4.34M-3.07M-2.54M-7.53M-1.69M-1.74M-1.21M-1.64M-989K-950K-955K-4.1M-14.33M-9.49M-3.85M-6.7M-5.1M-9.2M
CapEx % of Revenue9.46%8.85%2.88%2.1%3.41%4.38%2.89%2.92%2.2%3.71%4.12%2.81%3.68%3.08%2.33%2.12%6.46%1.51%1.65%1.27%2.02%1.43%1.52%1.6%5.27%16.34%12.31%5.77%11.04%10.02%24.86%
Acquisitions000000-59.12M00-163.92M-71.36M-1.35M198K0-17.04M-21.06M048K019K13K12K26K0000015M00
Investments-------------------------------
Other Investing-5.5M-3M-17M6.93M0-249K-6.68M-15.87M-929K-86K4.87M3K-192K-206K-2.81M-547K-797K-831K-46K-190K-105K-208K-56K1.25M-1.43M1.33M43K-452K-700K-4.5M-1.6M
Cash from Financing9.56M13.03M2.2M865K-1.64M-12.22M93.61M-1.49M-2.56M143.25M73.43M-2.81M-6.95M-3.05M-4.71M-2.85M-4.72M707K-2.43M743K-968K22.73M15.55M-8.03M-1.4M1.33M7.78M-4.46M30.5M10.6M1.8M
Debt Issued (Net)146K-2.46M-358K-2.77M-2.75M-3.08M94.65M-2.78M-2.79M152.79M73.59M0000-31K-1.54M-1.33M-4.2M-41K-2.76M3.79M-717K-6.25M-2.21M-176K6.37M-738K-12.5M10M1.2M
Equity Issued (Net)10.14M13.07M5.73M-559K-1.79M-1.91M-2M-2.74M-2.1M-1.61M-697K-1.39M-7.07M-2.2M-3.53M-3.06M-5.88M-330K1.77M1.27M418K19.47M19.65M660K809K1.5M1.05M-3.73M42.9M600K600K
Dividends Paid00000000000-3.41M-3.29M-2.97M-1.37M0000-486K-973K-533K000000000
Share Repurchases000-559K-1.79M-1.91M-2M-2.74M-2.1M-1.61M-697K-1.39M-7.07M-1.52M-3.53M-3.06M-5.88M-330K-611K-478K-50K0-54K0-663K0-612K-4.3M-3.4M00
Other Financing-731K2.42M-3.17M4.2M2.91M-7.22M949K4.03M2.33M-7.93M531K1.98M3.41M2.12M187K249K2.69M2.37M002.35M0-3.38M-2.44M00360K0100K00
Net Change in Cash18.07M11.45M-5.48M19.59M-15.66M-6.95M27.66M-7.94M1.48M-16.66M19.05M4.21M-4.27M24.63M-8.7M-13.79M5.38M12.92M2.74M10.33M-2.5M1.92M-184K-4.61M3.07M-10.28M11.35M-6.76M30.5M10.6M1.8M
Free Cash Flow12.83M-911K11.05M11.39M-15.87M-15.68M5.04M7.75M4.09M3.76M12.29M7.34M2.8M12.43M15.92M14.21M13.3M14.88M7.8M8.09M-2.71M-19.51M-17.18M-6.89M-6.21M-7.85M788K-2.87M-5.5M-7.3M-5.2M
FCF Margin %2.8%-0.21%2.84%3.22%-5.06%-5.25%1.99%2.81%1.56%1.98%6.82%5.03%1.93%8.83%12.09%11.88%11.41%13.33%7.42%8.53%-3.34%-28.15%-27.53%-11.57%-7.98%-8.95%1.02%-4.3%-9.06%-14.34%-14.05%
FCF Growth %3022.78%-108.25%-3.05%171.81%-1.22%-410.97%-35%89.38%8.85%-69.4%67.53%162.29%-77.5%-21.9%12.01%6.82%-10.6%90.82%-3.54%398.01%86.09%-13.57%-149.4%-10.88%20.88%-1096.19%127.49%47.89%24.66%-40.38%-940%
FCF per Share0.26-0.020.270.28-0.40-0.400.130.200.110.110.370.260.100.450.580.510.470.530.280.30-0.11-0.81-0.75-0.35-0.32-0.400.04-0.15-0.30-0.49-0.35
FCF Conversion (FCF/Net Income)1.10x3.90x-1.66x-0.61x0.27x0.17x-0.74x9.20x-2.60x2.92x1.83x2.86x1.11x1.04x2.39x2.27x5.28x1.91x0.29x1.29x-2.93x0.95x0.87x0.18x0.08x0.71x1.31x0.22x0.18x-0.47x1.03x
Interest Paid0000000000000000000000000000000
Taxes Paid0000000000000000000000000000000

Key Metrics

Growth RegimeAccelerating
ProfitabilityStrained
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Regulatory approval timeline delays

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality and Cash Disconnect

As reported in recent financial filings, Artivion's operating cash flow frequently diverges from net income, evidenced by a 2025Q1 OCF/NI ratio of 33.57, which highlights the significant impact of non-cash adjustments and working capital volatility on the company's reported bottom-line profitability metrics.

The wide variance between net income and operating cash flow suggests that accounting earnings are currently poor proxies for the company's actual cash-generating capacity. Investors should monitor whether this disconnect persists as the company scales its high-tech aortic device portfolio, as persistent reliance on non-cash adjustments may mask underlying operational inefficiencies.

Volatile Free Cash Flow Path

Based on the provided cash flow statements, Artivion's free cash flow trajectory remains inconsistent, with margins swinging from a negative 20.8% in 2025Q1 to a positive 14.0% in 2025Q3, reflecting the inherent difficulty in stabilizing cash generation during a period of aggressive strategic transition.

The erratic nature of free cash flow appears to be driven by the lumpy timing of capital expenditures and working capital requirements. This volatility warrants further investigation into whether the company can achieve sustainable positive free cash flow as it moves past the initial integration phases of its recent acquisitions.

Capital Intensity and Asset Replacement

According to historical data, Artivion's capital intensity has fluctuated significantly, peaking at a 23.7% CapEx-to-revenue ratio in 2025Q4, which suggests that the company is currently prioritizing heavy investment in manufacturing infrastructure to support its specialized aortic device production and global distribution capabilities.

The elevated capital spending appears necessary to maintain the clean-room environments and cryopreservation facilities required for its product lines. However, the high level of investment relative to revenue suggests that the company's cash flow will remain sensitive to the timing of these infrastructure projects for the foreseeable future.

Working Capital Drag on Liquidity

As indicated by the quarterly cash flow data, Artivion experienced a substantial $19.1 million working capital outflow in 2026Q1, which underscores the operational challenges of managing inventory and receivables within a complex, high-acuity medical device supply chain that relies on consignment-based sales models.

The recurring negative working capital swings suggest that the company's growth is currently consuming significant cash to fund inventory build-ups and accounts receivable. This trend may indicate that the company's cash conversion cycle is lengthening, which could pressure liquidity if revenue growth does not accelerate to offset these requirements.

AORT — Frequently Asked Questions

Quick answers to the most common questions about buying AORT stock.

How much cash does Artivion, Inc. (AORT) generate from operations?

Artivion, Inc. (AORT) generated $38.1M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Artivion, Inc.'s free cash flow?

Artivion, Inc. (AORT) reported negative free cash flow of $0.9M in 2025, indicating capital requirements exceeded cash from operations.

What is Artivion, Inc.'s capital expenditure (CapEx)?

Artivion, Inc. (AORT) spent $39.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.